

AbbVie Files Documentation with the Securities and Exchange Commission In Connection With a Registered Debt Offering

NORTH CHICAGO, ILLINOIS, U.S.A., May 8, 2015 – AbbVie Inc. ("AbbVie") (NYSE / CHX / Euronext Paris / SIX: ABBV) today informs its stockholders that it has filed a final prospectus supplement, a Current Report on Form 8-K, and an amendment to a previously-filed Schedule TO with the U.S. Securities and Exchange Commission ("SEC") in connection with a registered debt offering relating to AbbVie's previously announced agreement and plan of reorganization with Pharmacyclics, Inc.

AbbVie makes available free of charge on its website, its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, reports filed pursuant to Section 16 of the U.S. Securities Exchange Act of 1934 and amendments to those reports filed with or furnished to the SEC as soon as reasonably practicable after AbbVie electronically files these documents with, or furnishes them to, the SEC. These documents are posted on AbbVie's website at www.abbvieinvestor.com.

The SEC maintains a website that contains reports, proxy statements and other information regarding issuers that file electronically with the SEC. These materials may be obtained electronically by accessing the SEC's home page at <http://www.sec.gov>.

Copies of the above referenced information will also be made available, free of charge, upon written request to AbbVie Inc., Investor Relations, 1 North Waukegan Road, North Chicago, Illinois 60064, U.S.A.

SOURCE: AbbVie Inc.

CONTACT: AbbVie Inc., 1-847-938-8745